FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4366705086> ?p ?o ?g. }

• W4366705086 abstract "Objective: The aim of this study was to evaluate HER2-negative estrogen receptor and or progesterone receptor positive and describe treatments and overall survival (OS) of patients treated in a reference center. Methods: We enrolled retrospectively 5,510 patients in Perola Byington’s database from 2010 to 2021. After excluding patients without minimal complete records, a total of 4,855 were analyzed and clinical and pathological data were collected (date of diagnosis, first treatment, type of treatment, stage, type of surgery, disease-free survival, and OS). This study was approved by our ethics committee. Results: Most of our patients were diagnosed in stages I (26.9%) and II (38.2%). There was 23.4% in stage III, only 3.1% in stage IV, and 5.7% in stage 0, and in 2.6% the information was incomplete. The mean age at diagnosis was 57.6 years. We identified 4,761 (86.4% of 5,510) patients who underwent 4,848 surgical procedures. Of the total, 47.2% were mastectomies, 50.9% were sectorectomy, and 1.9% were adenectomy or adenomastectomy. Immediate reconstruction was done in 470 patients (69.8% underwent reconstruction with an expander, 22.3% with flap rotation and 7.9% with implants). The mean and median time between diagnosis and the beginning of treatment were analyzed; in the sample, it was observed that patients who were diagnosed in stages I, II, and IV had the same mean of 2.6 months, but stage IV had the lowest median 1.9 months. OS for patients diagnosed in stages I and II did not reach the median in the available period; for patients in stages III and IV, a median of 80.4 and 41.2 months of OS were identified, respectively. Conclusion: These are the first results of this large cohort of luminal patients treated in the public service of a referral center. Most patients are diagnosed in stage I or II and more than half undergo conservative surgery. Immediate reconstruction is not routinely performed. Stage III survival is 80.4 months and stage IV survival is 41.2 months in this analysis." @default.
• W4366705086 created "2023-04-24" @default.
• W4366705086 creator A5011030555 @default.
• W4366705086 creator A5028812536 @default.
• W4366705086 creator A5049871239 @default.
• W4366705086 creator A5052330359 @default.
• W4366705086 date "2022-01-01" @default.
• W4366705086 modified "2023-09-25" @default.
• W4366705086 title "A RETROSPECTIVE ANALYSIS OF 4,466 LUMINAL BREAST CANCER TREATED IN A REFERENCE CENTER" @default.
• W4366705086 doi "https://doi.org/10.29289/259453942022v32s2041" @default.
• W4366705086 hasPublicationYear "2022" @default.
• W4366705086 type Work @default.
• W4366705086 citedByCount "0" @default.
• W4366705086 crossrefType "proceedings-article" @default.
• W4366705086 hasAuthorship W4366705086A5011030555 @default.
• W4366705086 hasAuthorship W4366705086A5028812536 @default.
• W4366705086 hasAuthorship W4366705086A5049871239 @default.
• W4366705086 hasAuthorship W4366705086A5052330359 @default.
• W4366705086 hasBestOaLocation W43667050861 @default.
• W4366705086 hasConcept C121608353 @default.
• W4366705086 hasConcept C126322002 @default.
• W4366705086 hasConcept C141071460 @default.
• W4366705086 hasConcept C146357865 @default.
• W4366705086 hasConcept C151730666 @default.
• W4366705086 hasConcept C167135981 @default.
• W4366705086 hasConcept C207886595 @default.
• W4366705086 hasConcept C2780073493 @default.
• W4366705086 hasConcept C530470458 @default.
• W4366705086 hasConcept C71924100 @default.
• W4366705086 hasConcept C84606932 @default.
• W4366705086 hasConcept C86803240 @default.
• W4366705086 hasConcept C90924648 @default.
• W4366705086 hasConceptScore W4366705086C121608353 @default.
• W4366705086 hasConceptScore W4366705086C126322002 @default.
• W4366705086 hasConceptScore W4366705086C141071460 @default.
• W4366705086 hasConceptScore W4366705086C146357865 @default.
• W4366705086 hasConceptScore W4366705086C151730666 @default.
• W4366705086 hasConceptScore W4366705086C167135981 @default.
• W4366705086 hasConceptScore W4366705086C207886595 @default.
• W4366705086 hasConceptScore W4366705086C2780073493 @default.
• W4366705086 hasConceptScore W4366705086C530470458 @default.
• W4366705086 hasConceptScore W4366705086C71924100 @default.
• W4366705086 hasConceptScore W4366705086C84606932 @default.
• W4366705086 hasConceptScore W4366705086C86803240 @default.
• W4366705086 hasConceptScore W4366705086C90924648 @default.
• W4366705086 hasLocation W43667050861 @default.
• W4366705086 hasOpenAccess W4366705086 @default.
• W4366705086 hasPrimaryLocation W43667050861 @default.
• W4366705086 hasRelatedWork W2075475217 @default.
• W4366705086 hasRelatedWork W2362580737 @default.
• W4366705086 hasRelatedWork W2365274008 @default.
• W4366705086 hasRelatedWork W2899939825 @default.
• W4366705086 hasRelatedWork W3003870035 @default.
• W4366705086 hasRelatedWork W3032219018 @default.
• W4366705086 hasRelatedWork W3139267926 @default.
• W4366705086 hasRelatedWork W3141511544 @default.
• W4366705086 hasRelatedWork W3203015177 @default.
• W4366705086 hasRelatedWork W4319440053 @default.
• W4366705086 isParatext "false" @default.
• W4366705086 isRetracted "false" @default.
• W4366705086 workType "article" @default.